Cytosorbents Corporation, a critical care focused immunotherapy company, engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology worldwide. The company's flagship product is CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis; adjunctive therapy in other critical care applications; prevention and treatment of post-operative complications of cardiopulmonary bypass surgery; and prevention and treatment of organ dysfunction in brain-dead organ donors to increase the number and quality of viable organs harvested from donors. It also provides VetResQ device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals. In addition, the company develops CytoSorb-XL device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. Further, it is involved in the development of BetaSorb device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; and DrugSorb, an extracorporeal hemoperfusion cartridge designed to remove toxic chemicals from the blood. The company was formerly known as MedaSorb Technologies Corporation and changed its name to CytoSorbents Corporation in May 2010. The company was founded in 1997 and is based in Monmouth Junction, New Jersey.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CTSO
CUSIPN/A
Phone732-329-8885
Debt
Debt-to-Equity Ratio0.68
Current Ratio6.16
Quick Ratio5.99
Price-To-Earnings
Trailing P/E Ratio-37.03
Forward P/E Ratio-24.69
P/E GrowthN/A
Sales & Book Value
Annual Sales$15.15 million
Price / Sales23.49
Cash FlowN/A
Price / CashN/A
Book Value$0.36 per share
Price / Book32.92
Profitability
EPS (Most Recent Fiscal Year)($0.32)
Net Income$-8,460,000.00
Net Margins-56.06%
Return on Equity-88.39%
Return on Assets-38.47%
Miscellaneous
Employees84
Outstanding Shares30,030,000
Market Cap$355.88
Cytosorbents (NASDAQ:CTSO) Frequently Asked Questions
What is Cytosorbents' stock symbol?
Cytosorbents trades on the NASDAQ under the ticker symbol "CTSO."
How were Cytosorbents' earnings last quarter?
Cytosorbents Corp (NASDAQ:CTSO) announced its quarterly earnings results on Tuesday, May, 8th. The medical research company reported ($0.10) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.03. The medical research company had revenue of $4.93 million for the quarter, compared to the consensus estimate of $4.56 million. Cytosorbents had a negative net margin of 56.06% and a negative return on equity of 88.39%. View Cytosorbents' Earnings History.
When is Cytosorbents' next earnings date?
What price target have analysts set for CTSO?
5 brokers have issued 1 year price objectives for Cytosorbents' shares. Their forecasts range from $9.00 to $14.00. On average, they expect Cytosorbents' share price to reach $11.25 in the next twelve months. This suggests that the stock has a possible downside of 5.1%. View Analyst Ratings for Cytosorbents.
What is the consensus analysts' recommendation for Cytosorbents?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytosorbents in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
Are investors shorting Cytosorbents?
Cytosorbents saw a increase in short interest in the month of June. As of June 29th, there was short interest totalling 2,667,813 shares, an increase of 68.8% from the June 15th total of 1,580,330 shares. Based on an average trading volume of 658,144 shares, the short-interest ratio is presently 4.1 days. Approximately 10.3% of the shares of the company are sold short. View Cytosorbents' Current Options Chain.
Who are some of Cytosorbents' key competitors?
Some companies that are related to Cytosorbents include Tandem Diabetes Care (TNDM), Cardiovascular Systems (CSII), Atrion (ATRI), Orthofix International (OFIX), Cryolife (CRY), AtriCure (ATRC), OraSure Technologies (OSUR), Intersect ENT (XENT), Tactile Systems Technology (TCMD), Cerus (CERS), K2M Group (KTWO), SurModics (SRDX), AngioDynamics (ANGO), LeMaitre Vascular (LMAT) and Anika Therapeutics (ANIK).
Who are Cytosorbents' key executives?
Cytosorbents' management team includes the folowing people:
- Dr. Phillip P. Chan, CEO, Pres & Director (Age 48)
- Ms. Kathleen P. Bloch MBA, CPA, CFO & Sec. (Age 63)
- Mr. Vincent J. Capponi MS, Chief Operating Officer (Age 60)
- Dr. Eric R. Mortensen, Chief Medical Officer (Age 59)
- Dr. Robert H. Bartlett, Co-Chairman of Cardiac Surgery Advisory Board & Consultant (Age 79)
Has Cytosorbents been receiving favorable news coverage?
News coverage about CTSO stock has been trending somewhat positive on Monday, Accern reports. The research group identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Cytosorbents earned a media sentiment score of 0.24 on Accern's scale. They also gave news articles about the medical research company an impact score of 46.73 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
Who are Cytosorbents' major shareholders?
Cytosorbents' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Ballentine Partners LLC (0.07%). Company insiders that own Cytosorbents stock include Eric R Mortensen, Kathleen P Bloch, Michael G Bator, Phillip P Chan and Vincent Capponi. View Institutional Ownership Trends for Cytosorbents.
Which institutional investors are buying Cytosorbents stock?
CTSO stock was acquired by a variety of institutional investors in the last quarter, including Ballentine Partners LLC. Company insiders that have bought Cytosorbents stock in the last two years include Eric R Mortensen, Kathleen P Bloch, Michael G Bator, Phillip P Chan and Vincent Capponi. View Insider Buying and Selling for Cytosorbents.
How do I buy shares of Cytosorbents?
Shares of CTSO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cytosorbents' stock price today?
One share of CTSO stock can currently be purchased for approximately $11.85.
How big of a company is Cytosorbents?
Cytosorbents has a market capitalization of $355.88 million and generates $15.15 million in revenue each year. The medical research company earns $-8,460,000.00 in net income (profit) each year or ($0.32) on an earnings per share basis. Cytosorbents employs 84 workers across the globe.
How can I contact Cytosorbents?
Cytosorbents' mailing address is 7 DEER PARK DRIVE SUITE K, MONMOUTH JUNCTION NJ, 08852. The medical research company can be reached via phone at 732-329-8885 or via email at [email protected]
MarketBeat Community Rating for Cytosorbents (NASDAQ CTSO)
MarketBeat's community ratings are surveys of what our community members think about Cytosorbents and other stocks. Vote "Outperform" if you believe CTSO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTSO will underperform the S&P 500 over the long term. You may vote once every thirty days.
